|1.||Irikura, Mitsuru: 3 articles (01/2013 - 04/2004)|
|2.||Irie, Tetsumi: 3 articles (01/2013 - 04/2004)|
|3.||Ishitsuka, Yoichi: 3 articles (01/2013 - 04/2004)|
|4.||Park, Sang In: 2 articles (03/2015 - 01/2010)|
|5.||Shinohara, Yukito: 2 articles (07/2013 - 01/2009)|
|6.||Huang, Li: 2 articles (01/2010 - 10/2009)|
|7.||Lin, Li-E: 2 articles (01/2010 - 10/2009)|
|8.||Wu, Cong-Ming: 2 articles (01/2010 - 10/2009)|
|9.||Chen, Wen-Ting: 2 articles (01/2010 - 10/2009)|
|10.||Yao, Hong-Xia: 2 articles (01/2010 - 10/2009)|
05/01/2012 - "However, the evidence of ozagrel to reduce the long-term death or disability is limited and quality of these trials is insufficent hence, large-sample and high quality RCTs are warrented to confirm the efficacy of ozagrel for acute ischemic stroke."
05/01/2012 - "Ozagrel for acute ischemic stroke: a meta-analysis of data from randomized controlled trials."
05/01/2012 - "We searched seven databases, using the Cochrane Stroke Group search strategy and the terms of ozagrel and stroke. "
09/01/1996 - "The rates of suppressive effect in progressing stroke and complete recovery were higher in sodium ozagrel group. "
05/01/2012 - "The most severe adverse events of ozagrel were digestive hemorrhage and hemorrhagic stroke; however, there was no significant difference between the two groups. "
05/27/1996 - "However, renal functional parameters were significantly improved with the 2 mg/kg dose of OKY-046 administered after renal ischemia. "
08/01/1997 - "Twenty-eight heart were divided into four experimental groups consisting of 7 hearts each; Group I consisted of controls with zero-flow ischemia; Group II, perfusion with OKY-046 (10(-6) M) in zero-flow ischemia; Group III, controls with low-flow ischemia; and Group IV, perfusion with OKY-046 in low-flow ischemia. "
08/01/1997 - "OKY-046 was administered from forty-five minutes prior to the global ischemia. "
01/01/1997 - "Treatment with OKY-046 prevented the ischemia-induced reduction in the fetal body and placental weights. "
07/01/1996 - "Immediately after forebrain ischemia, OKY-046 (10 mg/kg) was injected intraperitoneally into the treated group. "
05/01/2005 - "With the initial diagnosis of cerebral infarction, we started therapy using sodium ozagrel. "
01/01/2003 - "Effect of ozagrel, a selective thromboxane A2-synthetase inhibitor, on cerebral infarction in rats. "
07/01/1986 - "OKY-046 at a dose of 0.3 mg/kg (i.v.) prevented the arachidonate-induced sudden death and also decreased the incidence of cerebral infarction induced by injection of arachidonate into the internal carotid artery in rabbits. "
07/01/2011 - "The combination therapy of fasudil (3 mg/kg i.p.) and ozagrel (10 mg/kg i.p.), which are noneffective doses, resulted in reduction of cerebral infarction, and the protective effect was observed up to 5 min, but not 3 h, after reperfusion. "
07/01/2003 - "[The clinical effect of combination therapy with edaravone and sodium ozagrel for acute cerebral infarction]."
|4.||Acute Kidney Injury (Acute Renal Failure)
01/01/1989 - "The administration of OKY-046, a selective TXA-synthase inhibitor in glycerol-treated rats (GTR), significantly prevented the decrease in Ccr (indicating a partial protection against the development of acute renal failure) (ARF) and the increase in urinary TXA2 excretion, while it did not significantly alter urinary prostaglandin (PG) excretion. "
06/15/1986 - "The inhibitor of thromboxane A2-synthetase OKY-046 enhanced sodium excretion and fractional excretion of sodium in normal and saline loaded animals whereas it partially prevented the reduction in sodium excretion and creatinine clearance and significantly increased fractional excretion of sodium in glycerol treated rats suggesting a partial protection against the development of acute renal failure."
|5.||Myocardial Ischemia (Ischemic Heart Diseases)
08/01/1997 - "In conclusion, OKY-046 has a significantly beneficial effect on metabolism during both myocardial ischemia and reperfusion."
09/01/1987 - "These results suggest that a marked increase in TXA2, with only a minimal change in PGI2, during exercise may contribute to exercise-induced myocardial ischemia, and that OKY-046 is useful in the treatment of CAD patients."
|8.||Thromboxane A2 (A2, Thromboxane)
|10.||fasudil (AT 877)
|1.||Activities of Daily Living (ADL)
|4.||Homologous Transplantation (Allograft)